A two part phase I multicenter ipen label study of DKN-01 in combination with weekly paclitaxel; Arm A; A dose escalation study in patients with relapsed or refractory esophageal cancer or gastro esophageal junction tumors; Arm B: A
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Leap Therapeutics, Inc.
Start Date
April 1, 2014
End Date
March 31, 2020
Administered By
Duke Cancer Institute
Awarded By
Leap Therapeutics, Inc.
Start Date
April 1, 2014
End Date
March 31, 2020